Adriana Herrera jumps ship from Novartis to Eisai

The US subsidiary of Japanese drug major Eisai (TYO: 4523) yesterday announced the immediate appointment of Adriana Herrera as senior vice president, Americas Commercial Oncology.

Ms Herrera will be responsible for developing and implementing the commercial strategy to accelerate the growth of Eisai's oncology business in the Americas region. She will lead the oncology commercial organization, bringing together all internal stakeholders and cross-functional teams to provide seamless and integrated service delivery to customers and patients.

Prior to joining Eisai, Ms Herrera spent 12 years at Novartis Oncology, where she most recently served as VP global disease lead lung cancer, responsible for the global commercialization of various late-stage assets and in-line targeted therapies. She held previous roles of increasing responsibility in marketing, sales and operations at Swiss pharma giant Novartis (NOVN: VX), as well as Bristol-Myers Squibb (NYSE: BMY), where she initially started her career in the industry.